Scinai Immunotherapeutics Balans Gezondheid
Financiële gezondheid criteriumcontroles 2/6
Scinai Immunotherapeutics has a total shareholder equity of $-7.3M and total debt of $19.8M, which brings its debt-to-equity ratio to -272.1%. Its total assets and total liabilities are $14.9M and $22.1M respectively.
Belangrijke informatie
-272.1%
Verhouding schuld/eigen vermogen
US$19.82m
Schuld
| Rente dekkingsratio | n/a |
| Contant | US$3.08m |
| Aandelen | -US$7.28m |
| Totaal verplichtingen | US$22.14m |
| Totaal activa | US$14.85m |
Recente financiële gezondheidsupdates
Recent updates
Here's Why BiondVax Pharmaceuticals (NASDAQ:BVXV) Can Afford Some Debt
Nov 10
Bionvax Pharmaceuticals GAAP EPS of -NIS0.02
Aug 25BiondVax, European Investment Bank agree on new terms to co's outstanding €24M loan
Aug 10We Think BiondVax Pharmaceuticals (NASDAQ:BVXV) Has A Fair Chunk Of Debt
Mar 31BiondVax Pharmaceuticals under pressure on pricing $12.1M ADSs follow-on offering
Jan 29Analyse van de financiële positie
Kortlopende schulden: SCNI has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Langlopende schulden: SCNI has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: SCNI has negative shareholder equity, which is a more serious situation than a high debt level.
Schuld verminderen: SCNI's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: SCNI has sufficient cash runway for 5 months based on last reported free cash flow, but has since raised additional capital.
Voorspelling contante baan: SCNI is forecast to have sufficient cash runway for 4 months based on free cash flow estimates, but has since raised additional capital.